Hospital
Tufts Medical Center, INC.
Tufts Medical Center, INC. was paid $3.81M by Medicaid between Jul 2018 and Mar 2022, across 135 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 19% of everything it billed.
33Billing provider infoTUFTS MEDICAL CENTER, INC.
BOSTON, MA 02111
BOSTON, MA 02111
33aNPI1851337141assigned 06/22/2006
33bProvider typeChildren's Hospital
28Total paid$3.81M
24GClaims58,871
24DCodes billed135
24AFirst – last monthJul 2018 – Mar 2022
Compared with peers
Next to other Children's Hospital providers in Massachusetts
Rank by total paid#2 of 6
Median peer was paid$26K
This provider vs. median148×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,909 | $404K | |
| 2019 | 14,800 | $1.06M | |
| 2020 | 9,660 | $642K | |
| 2021 | 23,978 | $1.32M | |
| 2022 | 6,524 | $386K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 19% | 4,960 | 4,753 | $731K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 18% | 4,894 | 4,621 | $689K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.1% | 1,567 | 1,517 | $307K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 7.6% | 2,026 | 1,931 | $289K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 7.2% | 1,784 | 1,765 | $274K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 6.3% | 1,757 | 1,752 | $242K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 4.6% | 2,155 | 2,024 | $177K |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 3.9% | 1,216 | 1,212 | $148K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.3% | 1,038 | 894 | $127K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.8% | 1,652 | 1,530 | $69K |
| 99205 | Prolong outpt/office vis | 1.7% | 506 | 504 | $66K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.7% | 361 | 353 | $65K |
123 more codes
| 92567 | 1.5% | 1,012 | $58K | |
| 76770 | 1.4% | 303 | $53K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 241 | $44K |
| 99285 | Emergency room visit (most serious) | <1% | 170 | $37K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 139 | $35K |
| 92015 | Determination of refractive state | <1% | 815 | $35K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 89 | $31K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,190 | $28K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 108 | $27K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 390 | $18K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 119 | $15K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 142 | $14K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,078 | $13K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 36 | $11K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 105 | $11K |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 81 | $10K |
| 93325 | <1% | 68 | $9K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 981 | $9K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $9K |
| 0002A | <1% | 159 | $7K | |
| 0001A | <1% | 157 | $7K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 942 | $7K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 15 | $6K |
| 92060 | <1% | 165 | $6K | |
| G0378 | Hospital observation service, per hour | <1% | 64 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 444 | $6K |
| 92587 | <1% | 25 | $5K | |
| 83735 | <1% | 1,072 | $5K | |
| 0071A | <1% | 131 | $5K | |
| 0072A | <1% | 123 | $5K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 136 | $5K |
| 91307 | <1% | 261 | $4K | |
| 97803 | <1% | 75 | $4K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 75 | $4K |
| 86140 | <1% | 926 | $4K | |
| 92557 | <1% | 26 | $4K | |
| 80051 | <1% | 449 | $3K | |
| 97010 | <1% | 38 | $3K | |
| 0004A | <1% | 82 | $3K | |
| 85027 | <1% | 638 | $3K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 474 | $3K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 14 | $3K |
| 72081 | <1% | 399 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 875 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 141 | $3K |
| 84439 | <1% | 306 | $2K | |
| 85652 | <1% | 859 | $2K | |
| 83540 | <1% | 338 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $2K |
| 82728 | <1% | 169 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 83 | $2K |
| 83690 | <1% | 283 | $1K | |
| 82247 | <1% | 1,134 | $1K | |
| 84466 | <1% | 149 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 25 | $1K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 77 | $1K |
| 82784 | <1% | 130 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 150 | $903.72 |
| 73630 | <1% | 28 | $871.66 | |
| 92579 | <1% | 138 | $854.56 | |
| 83516 | <1% | 78 | $810.75 | |
| 82248 | <1% | 1,271 | $787.50 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 23 | $736.23 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 23 | $736.23 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 31 | $696.85 |
| 72100 | <1% | 13 | $689.00 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,903 | $672.09 |
| 82565 | <1% | 697 | $671.04 | |
| 85730 | <1% | 170 | $652.50 | |
| 82040 | <1% | 133 | $629.62 | |
| 86850 | <1% | 99 | $628.14 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 141 | $623.09 |
| 92083 | <1% | 12 | $605.16 | |
| 80061 | Lipid panel | <1% | 64 | $604.96 |
| 73610 | <1% | 54 | $598.19 | |
| 90686 | <1% | 19 | $569.33 | |
| 82150 | <1% | 124 | $561.45 | |
| 80053 | Comprehensive metabolic panel | <1% | 44 | $488.58 |
| 84450 | <1% | 1,303 | $446.57 | |
| 92133 | <1% | 12 | $437.06 | |
| 85610 | <1% | 173 | $429.75 | |
| 83970 | <1% | 13 | $414.15 | |
| 84460 | <1% | 1,303 | $411.72 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 251 | $393.55 |
| 84702 | <1% | 27 | $370.98 | |
| 83615 | <1% | 1,021 | $360.41 | |
| 85007 | <1% | 188 | $344.09 | |
| 84156 | <1% | 108 | $322.45 | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 19 | $285.30 |
| 73130 | <1% | 13 | $275.60 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 12 | $263.64 |
| 86900 | <1% | 99 | $234.78 | |
| 86901 | <1% | 99 | $234.78 | |
| 73522 | <1% | 172 | $216.45 | |
| 84075 | <1% | 1,133 | $215.85 | |
| 81001 | <1% | 86 | $214.66 | |
| 80069 | <1% | 27 | $194.12 | |
| 86803 | <1% | 14 | $182.14 | |
| 73560 | <1% | 13 | $169.67 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 28 | $169.28 |
| 84484 | <1% | 16 | $156.57 | |
| 87340 | <1% | 15 | $141.30 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 39 | $139.92 |
| 84520 | <1% | 694 | $113.64 | |
| 82550 | <1% | 211 | $113.29 | |
| 85046 | <1% | 27 | $104.56 | |
| 82043 | <1% | 20 | $95.04 | |
| 81003 | <1% | 52 | $88.15 | |
| 84100 | <1% | 829 | $82.90 | |
| 82570 | <1% | 20 | $75.52 | |
| 84703 | <1% | 15 | $75.46 | |
| 81002 | <1% | 14 | $33.41 | |
| 82947 | <1% | 363 | $32.82 | |
| 91300 | 0% | 328 | $0.00 | |
| 82310 | 0% | 19 | $0.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 21 | $0.00 |
| 84550 | 0% | 58 | $0.00 | |
| 94760 | 0% | 1,111 | $0.00 | |
| 88342 | 0% | 66 | $0.00 | |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 23 | $0.00 |
| 93320 | 0% | 37 | $0.00 | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 0% | 71 | $0.00 |
| 88304 | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDONOVAN, STEVE (DIRECTOR OF FINANCIAL PLANNING)
| Provider | Location | Paid |
|---|---|---|
| Tufts Medical Center, INC. | Boston, MA | $164.34M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.